Q-omics provides the consensus-scored ZDHHC2 profile across patient tissues and cancer cell-line models. ZDHHC2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZDHHC2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZDHHC2 protein abundance shows 20,458 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, KIRC, and LSCC as cancer lineages where ZDHHC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC2 survival associations across molecular data types. ZDHHC2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC2 RNA expression–survival associations across cancer types. High ZDHHC2 expression shows unfavorable associations in STAD, but favorable associations in LUAD, BRCA, READ, KIRC and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZDHHC2 RNA expression.
This table summarizes ZDHHC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC2 shows lower tumor expression in KIRC, COAD, LUAD, LUSC, KIRP and BRCA. The KIRC box plot shows higher ZDHHC2 RNA expression in normal versus tumor tissue (log2 FC = −2.006, t-test p < 0.001).
This table shows molecular features associated with ZDHHC2 in patient tissues and cancer cell lines. In patient samples, ZDHHC2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
